Medical Oncologist | Research fellow @DFCI_BreastOnc | PhD student Translational Genomics @idibaps | @SOLTIyoung member | 🧬 Main focus: IO&breast cancer
Joined January 2011
- Tweets454
- Following514
- Followers753
- Likes1.4K
Can liquid biopsies help us better understand breast cancer brain mets? 🧠
In our phase II trial, paxalisib+trastuzumab showed limited activity in HER2+ BCBM, but our data suggest CSF ctDNA may better reflect tumor genomics and response than plasma.
🔗 doi.org/10.1158/2767-9764.CR…
Elia Seguí, MD retweeted
We’ve long treated HER2+ breast cancer similarly. Until everything changed.
Within 1 year, T-DXd moved earlier, palbo and tucatinib reshaped maintenance, some chemos are nearly gone, biomarkers guide us.
The right-sizing era for HER2+ BC has begun.
nature.com/articles/s41571-0… 🧵1/
Elia Seguí, MD retweeted
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial
aacrjournals.org/clincancerr…
Phase I study of patients with hormone receptor-positive/🧬HER2-negative metastatic #BreastCancer who had progressed on prior CDK4/6 inhibitors💊, the combination of avutometinib, abemaciclib, and fulvestrant demonstrated manageable toxicity and encouraging preliminary activity.
@adawaksmd
@elia_segui
@MarlaLipsycMD
@_mstalteri
@hparsons007
@AnnPartridgeMD
@DrDAbravanel
@stolaney1
@Nikhilwagle
@GShapiroMDPhD
@OncoAlert 🚨
Elia Seguí, MD retweeted
The true value of the #SOLTIYoung European Workshop lies in the conversations, learning and collaborative thinking it has made possible 🙌
Over three days, young breast cancer specialists from across Europe gathered in Barcelona to exchange perspectives, discuss unmet clinical needs and explore how clinical questions can be approached through academic research design.
Here are some of the key takeaways from the meeting:
▪️ International collaboration is essential to accelerate research and address shared clinical challenges.
▪️ The future of oncology depends on creating real opportunities for new generations to actively participate in research design.
▪️ Questions arising from daily clinical practice are the starting point for developing studies that have a real impact on patient care.
▪️ Academic and independent research remains essential to generate knowledge and move towards more precise medicine.
▪️ Connecting talent, experience, and fresh perspectives is the best way to build the future of breast cancer research.
Thank you to all the participants, mentors, and collaborating groups who made this pioneering initiative possible: Evandro De Azambuja, Oleg Gluz, Mafalda Oliveira, Gabe Sonke, Elie El Rassy, Meritxell Bellet, Eva Blondeaux, Guillermo Villacampa, Víctor Navarro, Austrian Breast & Colorectal Cancer Study Group (ABCSG), ASEICA - Asociación Española de Investigación sobre el Cáncer, Cancer Research @ UCC, EORTC - European Organisation for Research and Treatment of Cancer/BCG, Swiss Cancer Institute, Unicancer and WSG - Westdeutsche Studiengruppe GmbH.
Thank you to the collaborators of this initiative: Daiichi/Astrazeneca, MSD / Astrazeneca, Pfizer, Lilly, Menarini Stemline, Exact Sciences - Palex.
#beSOLTI #SYEW #SOLTIYoung #breastcancer
Elia Seguí, MD retweeted
Great few days at the @_SOLTI Young European Workshop in Barcelona
Great discussions on clinical trial design, new collaborations, and plenty of ideas to take forward
Thank you @elia_segui & @Rodrosb for making it happen!
Looking forward to the next steps!
@OncoAlert
Elia Seguí, MD retweeted
We are so incredibly lucky to work with the superstar @tess_omeara! She is multitalented-- an incredible colleague, absolutely wonderful with patients, and able to analyze complex single-cell data!
@DFCI_BreastOnc
Her parents told her she could be anything. Inspired by her mother’s work in medicine, Dr. Tess O’Meara (@tess_omeara) pursued a career in #BreastCancer research and patient care at #DanaFarber.
Learn more about her path and her work in this story.
Elia Seguí, MD retweeted
Metastasis kills most cancer patients and grows from invisible seeds. How do these seeds escape from attack by immune cells? These seeds harness stress hormones!🤯
thanks to @nyscf @parkerici for their support. Today at @Nature nature.com/articles/s41586-0…
Elia Seguí, MD retweeted
New 📰: Pembrolizumab and Paclitaxel in HR+/HER2- #BreastCancer with HER2-Enriched or Basal-Like Subtypes
🔓pubmed.ncbi.nlm.nih.gov/4156…
@BenedettaConte5 @fara_bm @TomasPascualMD @CHernandoM @MOliveira_MD @MuozMateu @elia_segui @AdelaRodrguezH1 @G_Villacampa @AnaVivancosVHIO @CCR_AACR
Elia Seguí, MD retweeted
Today, let’s talk triple-negative breast cancer 🎬
In this third video of SOLTI Young Perspectives, experts Elia Seguí (@elia_segui), MD (Dana-Farber Cancer Institute, 4CB) and Rodrigo Sánchez-Bayona (@Rodrosb), MD PhD (Hosp Univ 12 Octubre) share the latest updates, challenges, and controversies in this field.
Find out more on our YouTube channel 🔗 youtu.be/t4byJdF5z3k
This project is supported by a grant from Daiichi-Sankyo Europe GmbH (@EUdaiichisankyo)
#beSOLTI #SYPerspectives #SABCS25 #breastcancer
Elia Seguí, MD retweeted
Insights, debates, and practical takeaways, brought to you by SOLTI Young Perspectives! 🎬
Today, Elia Seguí (@elia_segui), MD (Dana-Farber Cancer Institute, 4CB) and Benjamin Walbaum (@benjiwal), MD (Hospital Clínico Universidad Católica de Chile) engage in an insightful discussion on luminal breast cancer treatment.
Don’t miss the full conversation 🔗 youtu.be/SI7TdIqPTv4?si=V56F…
This project is supported by a grant from Daiichi-Sankyo Europe GmbH
#beSOLTI #SYPerspectives #SABCS25 #breastcancer
Elia Seguí, MD retweeted
Today is THE day!
The post-SABCS 2025 talk by @DrHBurstein at @DFCI_BreastOnc just started!
Elia Seguí, MD retweeted
TMB not infrequent in ILC and at least more frequent than IDC-NST. Not confident however about TMB and IO in breast cancer. My limited clinical experience has been disappointing…
annalsofoncology.org/article…
Elia Seguí, MD retweeted
#PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com/TBT2025
Analyses of data from adjuvant studies of abemaciclib or ribociclib suggest that dose reductions have which of the following effects on efficacy?
87%No effect
6%↓ efficacy
6%↓ efficacy w/ ribo only
0%↓ efficacy w/ abema only
31 votes • Final results Elia Seguí, MD retweeted
#PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com/TBTeval25
👉🏽ALL CME🔗 integrityce.com/TBT2025
Your pt is a postmenopausal ♀️w/ g3 T2N1 ER+/PR+/HER2- IDC s/p BCS, adjuvant CT and RT. Which of the following is an approved therapeutic option for this patient?
0%AI
71%AI + CDK4/6 inhibition
11%Oral SERD + CDK4/6i
18%1&2
28 votes • Final results Elia Seguí, MD retweeted
32/32 #TumorBoardTuesday
🔑Messages
🔹Mgmt after adj CDK4/6i→unclear
🔹Tumor bx @ relapse→essential (ER/HER2, NGS)
🔹Biology & timing of relapse should guide tx
🔹Options: novel SERDs, AKT/PI3K tx, ADCs, trials, et al
🔹Future trials must stratify by prior adj CDK4/6i exposure
Elia Seguí, MD retweeted
31/32 #TumorBoardTuesday #bcsm
🧐 Q: How would you treat this patient❓
⬇️ Vote and discuss
29%Palbo+inavo+fulv
29%TROP2 ADC (SG/Dato)
29%SG + pembro
13%Other / clinical trial
31 votes • Final results Elia Seguí, MD retweeted
30/32 #TumorBoardTuesday #bcsm
👩⚕️Back to our case…
📋 Relapse biopsy:
🔹ILC, Gr 2
🔹ER 5%, PR 0%, HER2 IHC 0
🔹PD-L1 CPS 2
🔹NGS: CDH1, PIK3CA, TP53m
🔹TMB: 24 mut/Mb
Elia Seguí, MD retweeted
29/32 #TumorBoardTuesday
🧑🏫Mini Tweetorial🧑🏫
🌍RWD: Relapse after adj abema: clinical behavior
Median duration of 1L metastatic tx: 3 mo (IQR 1.6–5.0)
➡️ Suggests aggressive biology & endocrine resistance
🔗doi.org/10.1016/j.esmoop.202…
Elia Seguí, MD retweeted
28/32 #tumorboardtuesday
🧑🏫Mini Tweetorial🧑🏫
Relapse after adj abema: What now? @CCortiMD
🌍RWD
🔹Recurrence after adj abema+ET ~9%
🔹Phenotypic shift: ~50% of pts w/ paired samples showed ER loss @ recurrence
🔹@ relapse
-- TP53 pathway alt 90% (9/10)
-- ESR1m 1%
-- No RB1m
Elia Seguí, MD retweeted
27/32 #TumorBoardTuesday
🧐 Q: What is your next step❓
⬇️ Vote & discuss
6%Chemo/ADC (ET resistance)
94%Bx relapse: ER/HER2+NGS
0%Refer to clinical trial
31 votes • Final results